Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

Ascierto, Paolo A; Del Vecchio, Michele; Robert, Caroline; Mackiewicz, Andrzej; Chiarion-Sileni, Vanna; Arance, Ana; Lebbé, Céleste; Bastholt, Lars; Hamid, Omid; Rutkowski, Piotr; McNeil, Catriona; Garbe, Claus; Loquai, Carmen; Dreno, Brigitte; Thomas, Luc; Grob, Jean-Jacques; Liszkay, Gabriella; Nyakas, Marta; Gutzmer, Ralf; Pikiel, Joanna; Grange, Florent; Hoeller, Christoph; Ferraresi, Virginia; Smylie, Michael; Schadendorf, Dirk; Mortier, Laurent; Svane, Inge Marie; Hennicken, Delphine; Qureshi, Anila; Maio, Michele.
Lancet Oncol; 18(5): 611-622, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28359784